These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21641230)

  • 1. Optimizing targeted cancer therapy: towards clinical application of systems biology approaches.
    Sikkema AH; den Dunnen WF; Diks SH; Peppelenbosch MP; de Bont ES
    Crit Rev Oncol Hematol; 2012 May; 82(2):171-86. PubMed ID: 21641230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinome profiling of clinical cancer specimens.
    Parikh K; Peppelenbosch MP
    Cancer Res; 2010 Apr; 70(7):2575-8. PubMed ID: 20332226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic protein kinase inhibitors.
    Grant SK
    Cell Mol Life Sci; 2009 Apr; 66(7):1163-77. PubMed ID: 19011754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.
    Petricoin EF; Bichsel VE; Calvert VS; Espina V; Winters M; Young L; Belluco C; Trock BJ; Lippman M; Fishman DA; Sgroi DC; Munson PJ; Esserman LJ; Liotta LA
    J Clin Oncol; 2005 May; 23(15):3614-21. PubMed ID: 15908672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of cancer signaling networks by systems biology to develop therapies.
    Prasasya RD; Tian D; Kreeger PK
    Semin Cancer Biol; 2011 Jun; 21(3):200-6. PubMed ID: 21511035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linking the kinome and phosphorylome--a comprehensive review of approaches to find kinase targets.
    Sopko R; Andrews BJ
    Mol Biosyst; 2008 Sep; 4(9):920-33. PubMed ID: 18704230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide arrays for kinome analysis: new opportunities and remaining challenges.
    Arsenault R; Griebel P; Napper S
    Proteomics; 2011 Dec; 11(24):4595-609. PubMed ID: 22002874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
    Rowinsky EK
    J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A passage through systems biology to systems medicine: adoption of middle-out rational approaches towards the understanding of therapeutic outcomes in cancer.
    Majumder D; Mukherjee A
    Analyst; 2011 Feb; 136(4):663-78. PubMed ID: 21109854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative proteomics and phosphoproteomics reveal novel insights into complexity and dynamics of the EGFR signaling network.
    Morandell S; Stasyk T; Skvortsov S; Ascher S; Huber LA
    Proteomics; 2008 Nov; 8(21):4383-401. PubMed ID: 18846509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays.
    Wulfkuhle JD; Edmiston KH; Liotta LA; Petricoin EF
    Nat Clin Pract Oncol; 2006 May; 3(5):256-68. PubMed ID: 16683004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protease proteomics: revealing protease in vivo functions using systems biology approaches.
    Doucet A; Overall CM
    Mol Aspects Med; 2008 Oct; 29(5):339-58. PubMed ID: 18571712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards novel paradigms for cancer therapy.
    Pavet V; Portal MM; Moulin JC; Herbrecht R; Gronemeyer H
    Oncogene; 2011 Jan; 30(1):1-20. PubMed ID: 20935674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
    Abdollahi A; Folkman J
    Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.
    Poste G
    Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long road to colorectal cancer therapy: searching for the right signals.
    Hollande F; Pannequin J; Joubert D
    Drug Resist Updat; 2010; 13(1-2):44-56. PubMed ID: 20176501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
    Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
    Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.